drugset / Trial / NCT03077607

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

NCT03077607

Phase 1 Completed 36 enrolled Pfizer Medivation, Inc. · collab
Non-randomizedOpen-labelTreatment

Summary

This is a study in patients with advanced solid tumors for the investigation of P-gp inhibition and induction on the PK of talazoparib.

Timeline

Start
2016-11-07
Primary completion
2017-12-19
Completion
2018-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 100 mg Oral
Subject Rifampin Small molecule 600 mg Oral
Subject Talazoparib Small molecule 0.5 mg Oral
Subject Talazoparib Small molecule 1 mg Oral

Indications